Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
– Presentation highlights beneficial effects of chronic EDG-7500 treatment in preventing diastolic dysfunction in an animal model of non-obstructive hypertrophic cardiomyopathy (HCM) –
“EDG-7500 is a novel investigational therapy for the treatment of HCM with a differentiated mechanism of action,” said
Edgewise Presentation at ACC.24:
Session: From the bench to the bedside: Advances in heart failure & cardiomyopathies
Poster Presentation: 1087-05 - Chronic Treatment with the Novel Sarcomere Modulator EDG-7500 Improves Left Ventricular Distensibility and Cardiac Output Recruitment Under Stress in a Mini-pig Genetic Model of Non-Obstructed Hypertrophic Cardiomyopathy
Presenter:
Date:
The scientific poster will be available on the Edgewise website after it is presented.
About EDG-7500 for HCM
EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunction. Preclinical data in models of both obstructed and non-obstructed HCM suggest the ability to drive a broadly effective clinical response at a low risk of decreasing left ventricular ejection fraction below normal at all doses tested. Due to EDG-7500’s self-limiting mechanism on systolic contraction, the Company plans to investigate fixed-dose regimens of EDG-7500, thus potentially eliminating the echo-mediated dose titration and intense follow-up requirements of current therapy. The Company is advancing a randomized, placebo-controlled, single and multiple ascending dose Phase 1 trial evaluating safety, tolerability, PK and pharmacodynamics in healthy adults. To learn more about this trial (NCT06011317), go to clinicaltrials.gov.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328046868/en/
Edgewise Contacts
Investors:
ir@edgewisetx.com
Media:
media@edgewisetx.com
Source: